| 1 |
吴国明，钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
|
| 2 |
王洪武，金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
|
| 3 |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CACancer J Clin, 2021, 71(3): 209-249.
|
| 4 |
NSCLC Meta-Analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data[J]. Lancet (London, England), 2014, 383(9928): 1561-1571.
|
| 5 |
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J]. JClin Oncol , 2008, 26(21): 3552-3559.
|
| 6 |
Wakelee HA, Dahlberg SE, Keller SM, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial[J]. LancetOncol, 2017, 18(12): 1610-1623.
|
| 7 |
Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. New England J Med, 2018, 378(21): 1976-1986.
|
| 8 |
Hui R, Özgüroglu M, Villegas A, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage Ⅲ，unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study[J]. Lancet Oncol, 2019, 20(12): 1670-1680.
|
| 9 |
Cascone T. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial[J]. Nature Med, 2021, 27: 30.
|
| 10 |
Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J]. Immunity, 2007, 27(1): 111-122.
|
| 11 |
LiB, Chan HL, Chen P. Immune checkpoint inhibitors: Basics and challenges[J]. Curr Med Chem, 2019, 26(17): 3009-3025.
|
| 12 |
Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease[J]. Cancer Discov, 2016, 6(12): 1382-1399.
|
| 13 |
Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer | Cancer Research | American Association for Cancer Research[EB/OL]．[2022-04-24].
URL
|
| 14 |
Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2019, 158(1): 269-276.
|
| 15 |
Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC[J]. J Thorac Oncol, 2020, 15(5): 816-826.
|
| 16 |
Gao S, Li N, Gao S, et al. Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.[J]. J Clin Oncol, 2021, 39(15_suppl): 8522.
|
| 17 |
Lee J, Chaft J, Nicholas A, et al. PS01.05 surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage ⅠB-ⅢB NSCLC: LCMC3 trial primary analysis[J]. JThorac Oncol, 2021, 16(3): S59-S61.
|
| 18 |
Carbone D, Lee J, Kris M, et al. OA06.06 Clinical/biomarker data for neoadjuvant atezolizumab in resectable stage ⅠB-ⅢB NSCLC: Primary analysis in the LCMC3 Study[J]. JThorac Oncol, 2021, 16(3): S115-S116.
|
| 19 |
Eichhorn F, Klotz LV, Kriegsmann M, et al. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience[J]. Lung Cancer, 2021, 153: 150-157.
|
| 20 |
Tong BC, Gu L, Wang X, et al. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2022, 163(2): 427-436.
|
| 21 |
Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J]. New England JMed, 2022: NEJMoa2202170.
|
| 22 |
Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(11): 1413-1422.
|
| 23 |
Provencio M, Nadal E, Insa A, et al. OA20.01 long term survival in operable stage iiia NSCLCpatients treated with neoadjuvant nivolumab plus chemotherapy-nadim study[J]. J Thorac Oncol, 2021, 16(10): S883.
|
| 24 |
Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stage ⅢA(N2) non-small-cell lung cancer-A multicenter single-arm phase Ⅱ trial[J]. JClin Oncol, 2021, 39(26): 2872-2880.
|
| 25 |
Pless M, Stupp R, Ris HB, et al. Induction chemoradiation in stage ⅢA/N2 non-small-cell lung cancer: a phase 3 randomised trial[J]. Lancet (London, England), 2015, 386(9998): 1049-1056.
|
| 26 |
Zhao ZR, Yang CP, Chen S, et al. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage Ⅲ non-small-cell lung cancer[J]. Oncoimmunology, 2021, 10(1): 1996000.
|
| 27 |
Hellmann MD, Chaft JE, William WN, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint[J]. Lancet Oncol, 2014, 15(1): e42-50.
|
| 28 |
Huynh C, Sorin M, Rayes R, et al. Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer[J]. LancetOncol, 2021, 22(8): 1056-1058.
|
| 29 |
Pataer A, Kalhor N, Correa AM, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy[J]. JThorac Oncol , 2012, 7(5): 825-832.
|
| 30 |
Betticher DC, Hsu Schmitz SF, Tötsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage ⅢA pN2 non-small-cell lung cancer: 5-year follow-up of a phase Ⅱ study[J]. British JCancer, 2006, 94(8): 1099-1106.
|
| 31 |
Liang H, Yang C, Gonzalez-rivas D, et al. Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer[J]. Transl Lung Cancer Res, 2021, 10(1): 143-155.
|
| 32 |
Cascone T, Weissferdt A, Godoy MCB, et al. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer[J]. Nat Commun, 2021, 12(1): 5045.
|
| 33 |
Kebir S, Rauschenbach L, Galldiks N, et al. Dynamic O-(2-[18F] fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases[J]. Neuro-Oncology, 2016, 18(10): 1462-1464.
|
| 34 |
Billan S, Kaidar-Person O, Gil Z. Treatment after progression in the era of immunotherapy[J]. Lancet Oncology, 2020, 21(10): e463-e476.
|
| 35 |
Chaft JE, Rimner A, Weder W, et al. Evolution of systemic therapy for stages Ⅰ-Ⅲ non-metastatic non-small-cell lung cancer[J]. Nat RevClin Oncol, 2021, 18(9): 547-557.
|
| 36 |
Denis M, Duruisseaux M, Brevet M, et al. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors？[J]. Front Immunol, 2020, 11: 492.
|
| 37 |
Kaira K, Mouri A, Kato S, et al. A phase Ⅱ study of daily carboplatin plus irradiation followed by durvalumab for stage Ⅲ non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)[J]. BMC Cancer, 2020, 20(1): 961.
|
| 38 |
Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage ⅢA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase Ⅱ Trial[J]. J Clin Oncol, 2021, 39(26): 2872-2880.
|